LLY stock forecast: what analysts expect
Wall Street analysts covering Eli Lilly and Company currently rate the stock a Buy on average, with a mean 12-month price target of $1,299.01 — +6.5% versus the last price of $1,220.28. Targets reflect analyst opinion, not a guarantee.
LLY historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in LLY.
LLY annual returns by year
Congress trading in LLY
30 members of Congress have disclosed trading LLY — 42 purchases and 29 sales worth an estimated $1.6M. Most recent disclosure: Jun 10, 2026.
See who in Congress traded LLY →Insider activity in LLY
LLY's own executives and directors have made 0 open-market purchases ($0) and 3 sales ($11.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 10, 2026.
| Aug 10, 2026 | Zakrowski Donald A | SVP, Finance, & CAO | Sell | $2.4M |
| Aug 7, 2026 | Hakim Anat | EVP, GC & Secretary | Sell | $6.0M |
| Jun 10, 2026 | Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Sell | $2.9M |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY Key Statistics
LLY in plain English
- P/E ratio (41.0) — how many dollars you pay for each $1 of LLY's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
- ROE (102.29%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (33.53%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (0.57%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
LLY stock: frequently asked questions
What is Eli Lilly and Company's stock price today?
Eli Lilly and Company (LLY) last traded at $1,220.28 on the NYSE. Over the past 52 weeks the stock has traded between $655.10 and $1,249.45.
Is LLY stock a buy or a sell?
Wall Street analysts' consensus rating on LLY is "Buy", with an average 12-month price target of $1,299.01 — about +6.5% versus the current price of $1,220.28. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in LLY 10 years ago be worth today?
A $1,000 investment in Eli Lilly and Company made 10 years ago would be worth about $18,328 today (dividends reinvested) — a total return of 1,733%, or 33.8% per year.
Does LLY pay a dividend?
Yes. Eli Lilly and Company currently pays a dividend yielding about 0.57% per year at today's share price.
What is LLY's P/E ratio?
LLY trades at a trailing price-to-earnings ratio of 41.0, and 25.9 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade LLY stock?
Yes — 30 members of Congress have disclosed trades in LLY under the STOCK Act, totaling 42 purchases and 29 sales worth an estimated $1.6M.
What is Eli Lilly and Company's ticker symbol?
Eli Lilly and Company trades under the ticker symbol LLY on the NYSE.
Compare LLY with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.